RTI Biologics Beats Up on Analysts Yet Again
RTI Biologics (NAS: RTIX) reported earnings on Oct. 25. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), RTI Biologics met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share was unchanged.
Gross margins grew, operating margins increased, net margins contracted.
RTI Biologics logged revenue of $44.6 million. The eight analysts polled by S&P Capital IQ anticipated revenue of $44.2 million on the same basis. GAAP reported sales were 5.5% higher than the prior-year quarter's $42.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.05. The eight earnings estimates compiled by S&P Capital IQ averaged $0.04 per share. GAAP EPS of $0.05 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 48.7%, 300 basis points better than the prior-year quarter. Operating margin was 9.2%, 170 basis points better than the prior-year quarter. Net margin was 6.3%, 20 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $45.7 million. On the bottom line, the average EPS estimate is $0.05.
Next year's average estimate for revenue is $178.9 million. The average EPS estimate is $0.17.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 209 members out of 219 rating the stock outperform, and 10 members rating it underperform. Among 49 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 48 give RTI Biologics a green thumbs-up, and one give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on RTI Biologics is outperform, with an average price target of $4.62.
- Add RTI Biologics to My Watchlist.
The article RTI Biologics Beats Up on Analysts Yet Again originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.